Scientific Sessions 2024
/
Cardiomyopathy Potpourri 1
/
Prevalence, Clinical Characteristics, and Outcomes of Patients with Genotype-Positive Arrhythmogenic Cardiomyopathy Presenting with a Sentinel Sudden Cardiac Arrest
American Heart Association
2
0
Final ID: Sa2189
Prevalence, Clinical Characteristics, and Outcomes of Patients with Genotype-Positive Arrhythmogenic Cardiomyopathy Presenting with a Sentinel Sudden Cardiac Arrest
Abstract Body (Do not enter title and authors here): Background: Arrhythmogenic cardiomyopathy (ACM) is a genetic heart disease characterized by proclivity for ventricular arrhythmias and systolic dysfunction. Rarely, sudden cardiac arrest (SCA) is the presenting event in ACM. These individuals may have concealed disease with no appreciable structural manifestations on imaging. Aims: To determine the prevalence, clinical features, and outcomes of patients with genotype-positive ACM who presented with a sentinel SCA. Methods: In this retrospective study, 445 genotype-positive ACM patients evaluated from 1/2015-4/2024 were analyzed to identify those whose initial presentation was SCA. Pertinent demographic, clinical, genetic, and outcome data were extracted from the electronic medical record. Structural manifestations were defined by having one of the following on baseline TTE: EF < 50%, LVEDV >56 mL (male) or >51 mL (female), or regional RV akinesia, dyskinesia, or aneurysm. Categorical variables are presented as number (%), and continuous variables as median (IQR). Statistical analysis was done using Fisher’s exact test (categorical), t-test (continuous), and Logrank test (survival). Patients were censored at time of transplant, death, or last followup. Results: Overall, 14/445 (3%) ACM patients presented with sentinel SCA [71% male; median age at SCA 39 (IQR 30-46)]. The most common genetic substrates were DSP-encoded desmoplakin (n=4; 29%), LMNA-encoded lamin A/C (n=3; 21%), and PKP2-encoded plakophilin-2 (n=3; 21%). During a median followup of 8.4 years, 12 (86%) experienced appropriate ICD shocks, 8 (57%) required catheter ablation for ventricular arrhythmias, 6 (42%) underwent transplant, and 2 (14%) died of cardiac causes. Notably, 5 (35%) patients did not have evidence of structural disease during baseline evaluation. Compared to those with structural disease, this group was younger [median age 28 (IQR 21-29) vs 45 (IQR 41-48), p = 0.002] and less likely to undergo transplant [0 (0%) vs 6 (42%), p = 0.03]. Conclusions: Sentinel SCA is a rare presentation in ACM and may precede overt structural cardiac changes in a subset of younger patients. This population remains at increased risk for recurrent ventricular arrhythmias and often require advanced therapies.
Swain, William
( Mayo Clinic
, Rocheseter
, Minnesota
, United States
)
Garmany, Ramin
( Mayo Clinic
, Rochester
, Minnesota
, United States
)
Castrichini, Matteo
( Mayo Clinic
, Rochester
, Minnesota
, United States
)
Bos, Johan
( Mayo Clinic
, Rochester
, Minnesota
, United States
)
Neves, Raquel
( Mayo Clinic
, Rochester
, Minnesota
, United States
)
Ackerman, Michael
( Mayo Clinic
, Rochester
, Minnesota
, United States
)
Giudicessi, John
( Mayo Clinic
, Rochester
, Minnesota
, United States
)
Author Disclosures:
William Swain:DO NOT have relevant financial relationships
| Ramin Garmany:DO NOT have relevant financial relationships
| Matteo Castrichini:DO NOT have relevant financial relationships
| Johan Bos:DO NOT have relevant financial relationships
| Raquel Neves:DO NOT have relevant financial relationships
| Michael Ackerman:DO have relevant financial relationships
;
Consultant:Abbott:Active (exists now)
; Royalties/Patent Beneficiary:Thryv Therapeutics:Active (exists now)
; Royalties/Patent Beneficiary:Pfizer:Past (completed)
; Royalties/Patent Beneficiary:ARMGO Pharma:Active (exists now)
; Royalties/Patent Beneficiary:Anumana:Active (exists now)
; Royalties/Patent Beneficiary:AliveCor:Active (exists now)
; Consultant:Tenaya Therapeutics:Active (exists now)
; Consultant:Solid Biosciences:Active (exists now)
; Consultant:Medtronic:Active (exists now)
; Consultant:Invitae:Active (exists now)
; Consultant:Illumina:Active (exists now)
; Consultant:Daiichi Sankyo:Past (completed)
; Consultant:Bristol Myers Squibb:Active (exists now)
; Consultant:Boston Scientific:Active (exists now)
; Consultant:BioMarin Pharmaceutical:Active (exists now)
| John Giudicessi:DO have relevant financial relationships
;
Consultant:Avidity Biosciences:Active (exists now)
; Other (please indicate in the box next to the company name):Prolaio (equity/royalty sharing):Active (exists now)
; Research Funding (PI or named investigator):Tenaya Therapeutics:Active (exists now)